Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations

Vaccine

Volumn 27, Issue 34, 2009, Pages 4694-4703

  Snedecor, Sonya J ^a   Strutton, David R ^b   Ciuryla, Vincent ^b   Schwartz, Elissa J ^c   Botteman, Marc F ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b PFIZER INC   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

7 Valent pneumococcal vaccine; Mathematical model; S. pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; CHILD CARE; GROUPS BY AGE; HEALTH CARE QUALITY; HEALTH PROGRAM; INCIDENCE; INFECTION SENSITIVITY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MENINGITIS; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARRIER STATE; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNITY, HERD; INFANT; MIDDLE AGED; MODELS, THEORETICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; YOUNG ADULT;

EID: 67649470362     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.062     Document Type: Article

References (39)

1. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49 RR-9 (2000) 1-35
2. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54 36 (2005) 893-897
3. Posfay-Barbe K.M., and Wald E.R. Pneumococcal vaccines: do they prevent infection and how?. Curr Opin Infect Dis 17 3 (2004) 177-184
4. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
5. Hsu K.K., and Pelton S.I. Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2 5 (2003) 619-631
6. Huang S.S., Finkelstein J.A., and Lipsitch M. Modeling community- and individual-level effects of child-care center attendance on pneumococcal carriage. Clin Infect Dis 40 9 (2005) 1215-1222
7. Melegaro A., Gay N.J., and Medley G.F. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect 132 3 (2004) 433-441
8. Zhang Y., Auranen K., and Eichner M. The influence of competition and vaccination on the coexistence of two pneumococcal serotypes. Epidemiol Infect 132 6 (2004) 1073-1081
9. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5 3 (1999) 336-345
10. Temime L., Guillemot D., and Boelle P.Y. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance. Antimicrob Agents Chemother 48 6 (2004) 2206-2213
11. Haber M., Barskey A., Baughman W., Barker L., Whitney C.G., Shaw K.M., et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25 29 (2007) 5390-5398
12. Martin J.A., Hamilton B.E., Sutton P.D., Ventura S.J., Menacker F., and Kirmeyer S. Births: final data for 2004. Natl Vital Stat Rep 55 1 (2006) 1-101
13. Arias E. United States life tables 2003. Natl Vital Stat Rep 54 14 (2006) 1-40
14. Trotter C.L., Gay N.J., and Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 134 3 (2006) 556-566
15. Trotter C.L., Gay N.J., and Edmunds W.J. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162 1 (2005) 89-100
16. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285 13 (2001) 1729-1735
17. Goldblatt D., Hussain M., Andrews N., Ashton L., Virta C., Melegaro A., et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 192 3 (2005) 387-393
18. Ekdahl K., Ahlinder I., Hansson H.B., Melander E., Molstad S., Soderstrom M., et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 25 5 (1997) 1113-1117
19. Bennett N.M., Buffington J., and LaForce F.M. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 82 11 (1992) 1513-1516
20. Neuman H.B., and Wald E.R. Bacterial meningitis in childhood at the Children's Hospital of Pittsburgh: 1988-1998. Clin Pediatr (Phila) 40 11 (2001) 595-600
21. Feikin D.R., Schuchat A., Kolczak M., Barrett N.L., Harrison L.H., Lefkowitz L., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 90 2 (2000) 223-229
22. Dagan R., Givon-Lavi N., Zamir O., Sikuler-Cohen M., Guy L., Janco J., et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185 7 (2002) 927-936
23. Obaro S.K., Adegbola R.A., Banya W.A., and Greenwood B.M. Carriage of pneumococci after pneumococcal vaccination. Lancet 348 9022 (1996) 271-272
24. Givon-Lavi N., Fraser D., and Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 22 6 (2003) 524-532
25. Yeh S.H., Zangwill K.M., Lee H., Chang S.J., Wong V.I., Greenberg D.P., et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 21 19-20 (2003) 2627-2631
26. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., and Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 4 (1999) 1171-1176
27. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
28. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 16 (2007) 1784-1792
29. Lakshman R., Murdoch C., Race G., Burkinshaw R., Shaw L., and Finn A. Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy. Arch Dis Child 88 3 (2003) 211-214
30. Kaplan S.L., Mason Jr. E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 3 Pt 1 (2004) 443-449
31. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., and Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 3 (2005) e408-e413
32. CDC Behavioral Risk Factor Surveillance System. Centers for Disease Control and Prevention 2006 [cited March 10, 2009]; available from: http://apps.nccd.cdc.gov/brfss/display.asp?cat=IM&yr=2006&qkey=4408&state=UB.
33. Bridy-Pappas A.E., Margolis M.B., Center K.J., and Isaacman D.J. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 25 9 (2005) 1193-1212
34. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 21 (1991) 1453-1460
35. Musher D.M. Streptococcus pneumoniae. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. (2000), Churchill Livingstone, Philadelphia 2128-2147
36. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep 53 8 (2004) 177-178
37. Mahon B.E., Hsu K., Karumuri S., Kaplan S.L., Mason Jr. E.O., and Pelton S.I. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 24 14 (2006) 2514-2520
38. US Department of Health and Human Services (DHHS). National Center for Health Statistics. The 2005 National Immunization Survey, Hyattsville, MD: Centers for Disease Control and Prevention. 2007.
39. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae. Last accessed 9-9-2008.